中文摘要：

目的制备纯化脊髓损伤NogoA疫苗，疫苗免疫后分析NogoA疫苗的安全性及免疫效应。方法使用人工合成的NogoA-13肽，结合钥孔帽贝血蓝蛋白（KLH），增强其免疫原性并纯化。鼠龄3周Wistar雌性大鼠60只随机分为3组，A组：NogoA疫苗免疫组；B组：完全弗氏佐剂＋不完全弗氏佐剂组；C组：KLH免疫组；对大鼠进行腹腔免疫，使用ELISA检测抗体的滴度和与抗原抗体反应的结合能力。分析疫苗的安全性即大鼠自身免疫性脑脊髓膜炎（EAE）的发生率。结果A组大鼠血清中检测到抗NogoA-13肽IgG抗体的存在，倍比稀释后血清光密度（A）值呈现出规则的梯度。B、C组血清未检测到IgC抗体的存在。统计学分析发现A组与B、C两组血清不同倍比稀释浓度的A值存在明显的差异，差异具有统计学意义（P〈0．05）。B、C组之间及其与未免疫的阴性对照组血清A值的差异无统计学意义。大鼠EAE发生率为0。结论NogoA-13多肽疫苗免疫大鼠，可刺激出抗NogoA-13多肽抗体，抗体与抗原肽在体外可发生抗原抗体反应，验证了疫苗的有效性。实验动物未见EAE的表现，此多肽疫苗有较好的安全性。

英文摘要：

Objectives To prepare and purify NogoA vaccination for treatment of spinal cord injury. To study the safety and immune effect of this vaccination. Methods Artifical NogoA-13 polypeptide was coupled with KLH to improve the immunogenicity of vaccination. Sixty three-week-old Wistar female rats were divided into 3 groups randomly. Group A was immuned with NogoA vaccination, group B with incomplete freund＇s adjuvant ＋ complete freund＇s adjuvant; group C with KLH. Rats received abdominal cavity immunization. The level of antibody and the binding capability were detected with ELISA. The safety of vaccination was evaluated by the incidence and severity of experimental autoimmune encephalomyelitis （EAE）. Results The IgG antibody against the NogoA-13 polypeptide had been detected with ELISA in group A. A value of serum presented regular gradient during multiple proportion dilution. In group B and C, no antibodies were detected. The statistical significant difference in A value was revealed between group A and B, C group. No statistical significant difference was found in A value between group B and group C and non-immuned negative control serum. The features of EAE were not found in the immunized rats. Conclusions NogoA polypeptide vaccination can stimulate the antibody against the polypeptide. The immune effect of this vaccination is confirmed by binding reaction revealed in the ex vivo experiment. The good safety of vaccination is revealed by no features of EAE found in the immunized rats.